Collegium Pharmaceutical (COLL) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Collegium Pharmaceutical is the larger company by market cap ($755.0 million vs $727.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | OBX |
|---|---|---|
| Share price | $23.19 | $11.77 |
| Market cap | $754.96M | $727.07M |
| 1-day change | +0.04% | -3.52% |
| YTD return | -49.91% | — |
| 1-year return | -31.67% | — |
| 5-year return | +10.11% | — |
| P/E ratio (TTM) | 18.26 | — |
| Forward P/E | 3.20 | — |
| EPS (TTM) | $1.27 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $780.57M | — |
| Revenue growth (YoY) | +23.62% | — |
| Net income (latest FY) | $62.87M | — |
| Gross margin | 59.35% | — |
| Operating margin | 23.01% | — |
| Net margin | 8.05% | — |
| 52-week high | $50.79 | $49.97 |
| 52-week low | $21.43 | $11.62 |
| Distance from 52-week high | -54.34% | -76.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.30% | +231.35% |
| Average volume | 777.33K | 366.70K |
| Shares outstanding | 32.56M | 61.77M |
| Employees | 423 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
COLL vs OBX FAQ
Which is bigger, Collegium Pharmaceutical or Obsidian Therapeutics?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $754.96M compared with $727.07M for Obsidian Therapeutics (OBX).
Are Collegium Pharmaceutical and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.